Processing

Please wait...

Settings

Settings

1. WO2018112446 - USE OF APOE4 MOTIF-MEDIATED GENES FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE

Publication Number WO/2018/112446
Publication Date 21.06.2018
International Application No. PCT/US2017/066881
International Filing Date 15.12.2017
IPC
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/68 (2006.01)
G01N 33/53 (2006.01)
G01N 33/50 (2006.01)
C12Q 1/68 (2018.01)
A61P 25/28 (2006.01)
CPC
C12Q 1/6883
C12Q 2600/106
C12Q 2600/136
C12Q 2600/156
C12Q 2600/158
C12Q 2600/178
Applicants
  • SELONTERRA, INC. [US/US]; 1025 Alameda De Las Pulgas, Suite 126 Belmont, CA 94002, US
Inventors
  • URFER-BUCHWALDER, Anne; US
  • URFER, Roman; US
Agents
  • GEARHART, Richard; US
Priority Data
62/435,81518.12.2016US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF APOE4 MOTIF-MEDIATED GENES FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE
(FR) UTILISATION DE GÈNES À MÉDIATION PAR MOTIF APOE4 POUR LE DIAGNOSTIC ET LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
Abstract
(EN)
The present invention provides compositions and methods using APOE4 motif-mediated genes and expression products thereof for diagnosis, treatment and prevention of Alzheimer's disease and mild cognitive impairment. The present invention also relates to a method of identifying therapeutic agents to treat and diagnose Alzheimer's disease or mild cognitive impairment based on APOE4 motif-mediated genes.
(FR)
La présente invention concerne des compositions et des procédés utilisant des gènes à médiation par motif APOE4 et des produits d'expression de ceux-ci pour le diagnostic, le traitement et la prévention de la maladie d'Alzheimer et de la déficience cognitive légère. La présente invention concerne également un procédé d'identification d'agents thérapeutiques pour traiter et diagnostiquer la maladie d'Alzheimer ou la déficience cognitive légère sur la base de gènes à médiation par motif APOE4.
Also published as
EP2017880602
Latest bibliographic data on file with the International Bureau